DH vs. QTRX, AUNA, LYEL, EYPT, MLYS, PHAR, MLAB, ZYME, SVRA, and SLN
Should you be buying Definitive Healthcare stock or one of its competitors? The main competitors of Definitive Healthcare include Quanterix (QTRX), Auna (AUNA), Lyell Immunopharma (LYEL), EyePoint Pharmaceuticals (EYPT), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), Mesa Laboratories (MLAB), Zymeworks (ZYME), Savara (SVRA), and Silence Therapeutics (SLN). These companies are all part of the "medical" sector.
Quanterix (NASDAQ:QTRX) and Definitive Healthcare (NASDAQ:DH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation.
Quanterix received 245 more outperform votes than Definitive Healthcare when rated by MarketBeat users. Likewise, 61.66% of users gave Quanterix an outperform vote while only 30.99% of users gave Definitive Healthcare an outperform vote.
Quanterix has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Definitive Healthcare has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.
Quanterix has higher earnings, but lower revenue than Definitive Healthcare. Quanterix is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.
Quanterix has a net margin of -28.82% compared to Quanterix's net margin of -78.16%. Quanterix's return on equity of 0.51% beat Definitive Healthcare's return on equity.
Quanterix presently has a consensus price target of $30.60, indicating a potential upside of 77.08%. Definitive Healthcare has a consensus price target of $9.94, indicating a potential upside of 75.39%. Given Definitive Healthcare's stronger consensus rating and higher probable upside, research analysts plainly believe Quanterix is more favorable than Definitive Healthcare.
In the previous week, Quanterix and Quanterix both had 6 articles in the media. Definitive Healthcare's average media sentiment score of 0.97 beat Quanterix's score of 0.22 indicating that Quanterix is being referred to more favorably in the media.
86.5% of Quanterix shares are owned by institutional investors. Comparatively, 98.7% of Definitive Healthcare shares are owned by institutional investors. 6.9% of Quanterix shares are owned by insiders. Comparatively, 14.8% of Definitive Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Quanterix beats Definitive Healthcare on 11 of the 17 factors compared between the two stocks.
Get Definitive Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for DH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Definitive Healthcare Competitors List
Related Companies and Tools
